RARE:NASDAQ
Ultragenyx Pharmaceutical Inc
30,77 $
arrow_upward
+5,20%(+1,52) 1 d.
30,00 $
arrow_downward
-2,50% (-0,77)bedtimePēctirdzniecības
Slēgts: 26. jūn., 16:00:01 GMT-4 · USD
search
Visi simboli
1 d.
5 d.
1 m.
6 m.
Š.g.
1 g.
5 g.
Maks.
| Simbols | Cena | Izmaiņas | % izmaiņu |
|---|
insights_autoNotiek galveno ieskatu ģenerēšana par šādu tēmu: RARE…
Atvērt
29,39 $
Augsta
30,99 $
Zema
29,36 $
Tirgus kapitalizācija
3,03 mljrd.
Vid. apjoms
1,77 milj.
Apjoms
17,18 milj.
Augstākā 52 ned.
42,37 $
Zemākā 52 ned.
18,29 $
Peļņa uz vienu akciju
-6,10 $
Beta
0,37
Apgrozībā esošās akcijas
98,49 milj.
Darbinieku skaits
1 tūkst.
Atvērt
29,39 $
Augsta
30,99 $
Zema
29,36 $
Tirgus kapitalizācija
3,03 mljrd.
Vid. apjoms
1,77 milj.
Apjoms
17,18 milj.
Augstākā 52 ned.
42,37 $
Zemākā 52 ned.
18,29 $
Peļņa uz vienu akciju
-6,10 $
Beta
0,37
Apgrozībā esošās akcijas
98,49 milj.
Darbinieku skaits
1 tūkst.
Ziņas un raksti
No avotiem tīmeklī
Stock Traders Daily
·
pirms 8 stundām
Liquidity Mapping Around (RARE) Price Events
Profils
Ultragenyx Pharmaceutical Inc. is an American biopharmaceutical company involved in the research and development of novel products for treatment of rare and ultra-rare genetic diseases for which there are typically no approved treatments and high unmet medical need. The company works with multiple drug modalities including biologics, small molecule, gene therapies, and ASO and mRNAs in the disease categories of bone, endocrine, metabolic, muscle and CNS diseases.
Ultragenyx is based in Novato, CA and Brisbane, CA and has a presence in the Boston area, including a gene therapy plant under construction as of 2021. The company’s Latin American headquarters is located in Miami.
Ultragenyx collaborates on product development with other companies including GeneTX, Kyowa Hakko Kirin, Mereo Biopharma and Daiichi Sankyo. Ultragenyx has three products Burosumab, Triheptanoin and Vestronidase alfa that have received FDA approval and several others currently in clinical trials. The company also holds the non-US commercial rights to Regeneron’s evinacumab-dgnb, which is approved by the FDA and EMA. Wikipedia
Par “Ultragenyx Pharmaceutical Inc”
ĢenerāldirektorsEmil Kakkis
Darbinieki1,37 tūkst.
Dibināšanas datums2010
Galvenais birojsNovato, Kalifornija, Amerikas Savienotās Valstis
Sektors-
Tīmekļa vietneultragenyx.com
MI saturā var būt kļūdas. Uzzināt vairāk